TITLE:
Epidemiology of EGFR Mutation in Adenocarcinoma NSCLC Patients in India: A Systematic Review and Meta-Analysis
AUTHORS:
Ankita Jain, Kumar Prabhash, Venkatraman Radhakrishnan, Shashank Srinivasan
KEYWORDS:
Epidemiology, Epidermal Growth Factor Receptor, Adenocarcinoma, Non-Small Cell Lung Cancer, India
JOURNAL NAME:
Advances in Lung Cancer,
Vol.13 No.1,
March
14,
2024
ABSTRACT: Studies
reporting the Indian prevalence of Epidermal Growth Factor Receptor (EGFR) mutation are
mostly single centers with small sample sizes. This systematic review and meta-analysis
summarized the available evidence of EGFR
mutation epidemiology in Indian patients with adenocarcinoma (ADC) Non-Small
Cell Lung Cancer (NSCLC). We conducted a structured literature search in
PubMed, and EMBASE databases from January 2004 through October 2019. The primary outcome of
interest was prevalence of EGFR mutation by gender, smoking status, and mutation subtype. The
review included 34 studies. EGFR mutation prevalence was 39.5% in patients with
ADC, and significantly higher in females, non-smokers, and patients with exon
19 deletions. The EGFR mutation frequency in Indian patients with ADC was
higher than reported in Caucasians but at a lower range of that reported in East Asians. These findings support the use of EGFR
mutation testing to guide choice of treatment.